Taxotere and Xeloda for prostate cancer – pro
The Xeloda and Taxotere regimen is supported by several phase II studies and is also in a clinical study, NCT00258284: Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer. This study is ongoing, but not recruiting participants.
The available studies in metastatic or neaodjuvant setting show some responses but the most recent study of 2008 was dissapointing. “A total of 15 patients were treated, of whom 6 (40%) experienced a 50% or greater decrease in prostate specific antigen with infrequent diarrhea or hand-foot syndrome. Eleven patients underwent radical prostatectomy. There were no pathological complete responses and 4 patients demonstrated mild histological changes, including focal necrosis and vacuolated cytoplasm. While there was no discernable pattern of increased thymidine phosphorylase expression, 4 specimens showed decreased survivin expression, suggesting a possible mechanism for chemotherapy induced apoptosis. There was no correlation of prostate specific antigen response and survivin expression, and no increase in serum CK18Asp396. ”
Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, Montie J, Sarkar FH, Shah RB, Hussain M.Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer J Urol. 2008 Mar;179(3):911-5; discussion 915-6.
C. Soto, S. Reyes, F. Delgadillo, M. Ramirez, L. Torrecillas, L. Perez, H. Benitez, G. Cervantes, R. Zamora, A. Silva Capecitabine (X) plus docetaxel (T) vs capecitabine plus paclitaxel (P) vs sequential capecitabine then taxane in anthracycline pretreated patients (pts) with metastatic Proc Am Soc Clin Oncol 22: 2003 (abstr 28)
Jean-Marc Ferrero et al, Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer Cancer Cytopathology
Volume 107 Issue 4, Pages 738 – 745